September 30, 2014
1 pm to 2 pm EDT

Sponsored by

Webinar Description:

The general purpose of our translational research studies is to identify clinical tools for the detection of subclinical parenchymal lung disease. Our present studies focus on identifying peripheral blood biomarkers that could aid in the detection of subclinical interstitial lung disease and risk-stratify isubjects at risk of developing pulmonary fibrosis.

Learning Objectives:

  • Outline the rationale for early detection of Pulmonary Fibrosis
  • Describe phenotypic characteristics of Subclinical Interstitial Lung Disease (ILD) in at risk populations
  • Identify a strategy to select blood biomarkers for Subclinical ILD
  • Discuss how our translational research studies could improve the diagnosis and treatment of ILD


Ivan O. RosasIvan O. Rosas, MD

Assistant Professor of Medicine
Harvard Medical School in Boston, Massachusetts


Ivan O. Rosas, MD is Assistant Professor of Medicine at Harvard Medical School in Boston, Massachusetts. He is Director of the Interstitial Lung Disease Program at the Brigham and Women's Hospital and Director of the Pulmonary Fibrosis Research Program at the Lovelace Respiratory Research Institute in Albuquerque New Mexico. Dr. Rosas completed his Pulmonary and Critical Care Fellowship training at Johns Hopkins Hospital and a Research Fellowship at the National Heart Lung and Blood Institute Intramural Program. Dr. Rosas’ translational research program focuses on identifying novel molecular targets for diagnosis and treatment of pulmonary fibrosis and the development of strategies to prevent the development of interstitial lung disease in at risk populations. (List of Publications:

Cost: No cost!